Literature DB >> 8718682

Specific cleavage of target RNAs from HIV-1 with 5' half tRNA by mammalian tRNA 3' processing endoribonuclease.

M Nashimoto1.   

Abstract

Mammalian tRNA 3' processing endoribonuclease (3' tRNase) can be converted to an RNA cutter that recognizes four bases, with about a 65-nt 3'-truncated tRNA(Arg) or tRNA(Ala). The 3'-truncated tRNA recognizes the target RNA via four base pairings between the 5'terminal sequence and a sequence 1-nt upstream of the cleavage site, resulting in a pre-tRNA-like complex (Nashimoto M, 1995, Nucleic Acids Res 23:3642-3647). Here I developed a general method for more specific RNA cleavage using 3' tRNase. In the presence of a 36-nt 5' half tRNA(Arg) truncated after the anticodon, 3' tRNase cleaved the remaining 56-nt 3' half tRNA(Arg) with a 19-nt 3' trailer after the discriminator. This enzyme also cleaved its derivatives with a 5' extra sequence or nucleotide changes or deletions in the T stem-loop and extra loop regions, although the cleavage efficiency decreases as the degree of structural change increases. This suggests that any target RNA can be cleaved site-specifically by 3'tRNase in the presence of a 5' half tRNA modified to form a pre-tRNA-like complex with the target. Using this method, two partial HIV-1 RNA targets were cleaved site-specifically in vitro. These results also indicate that the sequence and structure of the T stem-loop domain are important, but not essential, for the recognition of pre-tRNAs by 3' tRNase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8718682      PMCID: PMC1369392     

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  16 in total

1.  Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers.

Authors:  Masato Tamura; Chikako Nashimoto; Noriko Miyake; Yasushi Daikuhara; Kozo Ochi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

2.  A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2004-06-28       Impact factor: 16.971

3.  The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2004-08-18       Impact factor: 16.971

4.  RNA heptamers that direct RNA cleavage by mammalian tRNA 3' processing endoribonuclease.

Authors:  M Nashimoto; S Geary; M Tamura; R Kaspar
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

5.  Distribution of both lengths and 5' terminal nucleotides of mammalian pre-tRNA 3' trailers reflects properties of 3' processing endoribonuclease.

Authors:  M Nashimoto
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

6.  A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

Review 7.  TRUE Gene Silencing.

Authors:  Masayuki Nashimoto
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

8.  Transfer RNA as a source of small functional RNA.

Authors:  Megumi Shigematsu; Shozo Honda; Yohei Kirino
Journal:  J Mol Biol Mol Imaging       Date:  2014

9.  TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents.

Authors:  Arisa Haino; Tatsuya Ishikawa; Mineaki Seki; Masayuki Nashimoto
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

10.  Elimination of specific miRNAs by naked 14-nt sgRNAs.

Authors:  Masayuki Takahashi; Reyad A Elbarbary; Mayumi Abe; Mari Sato; Tetsuo Yoshida; Yoji Yamada; Masato Tamura; Masayuki Nashimoto
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.